() said revenues had more than doubled and trading profits for the year to the end of December were in line with City forecasts as it provided investors with a progress report.
The speciality pharma company said it expects sales to be £97.5mln - up from £48.3mln a year earlier.
CEO John Dawson tells Proactive: 'It's never been so busy and exciting - the prospects are really good.''
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Alliance Pharma PLC named herein, including the promotion by the Company of Alliance Pharma PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE